Evidence map›Paper›PMID 41970676›Full record

ReviewEndoscopy international open2026

Post-inflammatory polyps and risk of dysplasia in inflammatory bowel disease: Wolves in sheep's clothing?

Elena De Cristofaro, Antonio Fonsi, Giovanni Monteleone, Irene Marafini

Abstract readReview
In one paragraph

Review in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elena De CristofaroGastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.ORCID 0000-0003-2818-916X
Antonio FonsiDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Giovanni MonteleoneGastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
Irene MarafiniGastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with longstanding and extensive inflammatory bowel disease (IBD) have an enhanced risk of colorectal cancer (CRC), which accounts for up to 10% of all IBD-related deaths. Chronicity of bowel inflammation, co-existence of primary sclerosing cholangitis, and a family history of sporadic colorectal cancer represent further risk factors for development of CRC. Colon post-inflammatory polyps are believed to be another risk factor for IBD-associated CRC, even though it remains unclear how presence of such lesions could influence CRC development. Although earlier observational studies suggested an association between post-inflammatory polyps and colorectal neoplasia, more recent studies have indicated that these lesions do not independently increase neoplasia risk. However, they may, nonetheless, complicate surveillance by obscuring dysplastic lesions, particularly when numerous, and they are best regarded as markers of chronic and recurrent mucosal inflammation. Moreover, emerging evidence suggests that a minority of post-inflammatory-like lesions may conceal or coexist with dysplasia, underscoring the diagnostic challenge posed by polypoid lesions in chronically inflamed mucosa. In this article, we review the available data about the association between post-inflammatory polyps and development of CRC in IBD and discuss how advances in technology, particularly development of artificial intelligence models integrated with endoscopy, may contribute to their appropriate management.

Indexed as

Colorectal cancerEndoscopy Lower GI TractInflammatory bowel diseasePolyps / adenomas / ...

Identifiers

PMID41970676
PMCPMC13063304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.